Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
VIENNA, Oct. 15, 2025 /PRNewswire/ -- The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD…
New international study led by Kemira identifies where people are most vulnerable if their community suddenly loses access to clean…
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies…
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a…
New proprietary research from Oriflame redefines beauty as a powerful driver of wellbeing STOCKHOLM, Oct. 8, 2025 /PRNewswire/ -- Global…
BERLIN, Oct. 7, 2025 /PRNewswire/ -- New research presented today at UEG Week 2025 shows that microplastics – plastic particles smaller…
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by The Hong Kong University of Science and Technology…
19th year of survey reveals cybersecurity remains top concern as workforce-related risks fall on global risk agenda DUBLIN, Oct. 1,…